Asia Pacific Antibody-Drug Conjugates Market - Forecasts from 2019 to 2024
The Asia Pacific antibody-drug conjugates (ADCs) market is expected to grow at a CAGR of 27.64% to reach a market size of USD2,271.411 million by the end of 2024. Antibody-drug conjugates are the novel and emerging class of anti-cancer therapies consisting of empowered monoclonal antibodies (mAbs) designed to harness the targeting ability of monoclonal antibodies by linking them to cell-killing agents. They consist of covalently linked monoclonal antibodies to small molecule drugs that target a specific cancer cell to reduce systemic toxicity. They also increase the cell-killing potential of monoclonal antibodies (mAbs) and confer higher tumor selectivity resulting in increased tolerability of the drug. The robust growth in the market may be attributed to the extensive research and development activities in the field of antibody-drug conjugates. However, the high cost of production of ADCs coupled with the difficult upstream and downstream processing might impede the market growth during the given forecast period.
The Asia Pacific antibody-drug conjugates Market – Forecasts from 2019 to 2024 is an exhaustive study which aims to present the key market trends through various chapters focusing on different aspects of the market. The study provides a detailed market overview through the market dynamics sections which detail key market, drivers, restraints, and opportunities in the current market. The report analyzes key opportunity regional markets, and the current technology penetration through lifecycle analysis. The report also analyzes the market through comprehensive market segmentation by the target, by indication, and by country.
The Asia Pacific antibody-drug conjugates market on segmented based on target, indication, and country. Based on target the market has been segmented into CD 30, CD 22, and HER 2. By indication, the market is segmented into haematologic malignancies and non-haematologic malignancies.
Country-wise analysis has been provided with detailed analysis and forecast for the period 2018 to 2024, taking 2018 as the base year. The regional market has been broken down into China, India, Australia, and others. A thorough analysis and forecast have been done along with the prevailing market trends and opportunities which each of these countries presents for the manufacturers.
Major players in the Asia Pacific antibody-drug conjugates market have been covered along with their relative competitive position and strategies. The report also mentions recent deals and investments of different market players over the last year. The company profiles section details the business overview, financial performance for the past three years, key products and services being offered along with the recent developments of these important players in the Asia Pacific antibody-drug conjugates market.
Segmentation
The Asia Pacific antibody-drug conjugates market has been analyzed through the following segments:
The Asia Pacific antibody-drug conjugates Market – Forecasts from 2019 to 2024 is an exhaustive study which aims to present the key market trends through various chapters focusing on different aspects of the market. The study provides a detailed market overview through the market dynamics sections which detail key market, drivers, restraints, and opportunities in the current market. The report analyzes key opportunity regional markets, and the current technology penetration through lifecycle analysis. The report also analyzes the market through comprehensive market segmentation by the target, by indication, and by country.
The Asia Pacific antibody-drug conjugates market on segmented based on target, indication, and country. Based on target the market has been segmented into CD 30, CD 22, and HER 2. By indication, the market is segmented into haematologic malignancies and non-haematologic malignancies.
Country-wise analysis has been provided with detailed analysis and forecast for the period 2018 to 2024, taking 2018 as the base year. The regional market has been broken down into China, India, Australia, and others. A thorough analysis and forecast have been done along with the prevailing market trends and opportunities which each of these countries presents for the manufacturers.
Major players in the Asia Pacific antibody-drug conjugates market have been covered along with their relative competitive position and strategies. The report also mentions recent deals and investments of different market players over the last year. The company profiles section details the business overview, financial performance for the past three years, key products and services being offered along with the recent developments of these important players in the Asia Pacific antibody-drug conjugates market.
Segmentation
The Asia Pacific antibody-drug conjugates market has been analyzed through the following segments:
- By Target
- CD 30
- CD 22
- HER 2
- By Indication
- Haematologic Malignancies
- Non-Haematologic Malignancies
- By Country
- China
- India
- Australia
- Others
1. INTRODUCTION
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Currency
1.5. Assumptions
1.6. Base, and Forecast Years Timeline
2. RESEARCH METHODOLOGY
2.1. Research Design
2.2. Secondary Sources
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1. Market Segmentation
4.2. Market Drivers
4.3. Market Restraints
4.4. Market Opportunities
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Competitive Rivalry in the Industry
4.6. Life Cycle Analysis - Regional Snapshot
4.7. Market Attractiveness
5. ASIA PACIFIC ANTIBODY-DRUG CONJUGATES MARKET BY TARGET
5.1. CD
5.2. CD
5.3. HER
6. ASIA PACIFIC ANTIBODY-DRUG CONJUGATES MARKET BY INDICATION
5.1. Haematologic Malignancies
5.2. Non-Haematologic Malignancies
7. ASIA PACIFIC ANTIBODY-DRUG CONJUGATES MARKET BY COUNTRY
7.1. China
7.2. India
7.3. Australia
7.4. Others
8. COMPETITIVE INTELLIGENCE
8.1. Market Positioning Matrix and Ranking
8.2. Recent Investments and Deals
8.3. Strategies of Key Players
9. COMPANY PROFILES
9.1. Takeda Pharmaceutical Company Limited
9.2. F. Hoffmann-La Roche Ltd.
9.3. Pfizer Inc.
9.4. Biotest AG
9.5. Astellas Pharma Inc.
9.6. Lonza
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Currency
1.5. Assumptions
1.6. Base, and Forecast Years Timeline
2. RESEARCH METHODOLOGY
2.1. Research Design
2.2. Secondary Sources
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1. Market Segmentation
4.2. Market Drivers
4.3. Market Restraints
4.4. Market Opportunities
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Competitive Rivalry in the Industry
4.6. Life Cycle Analysis - Regional Snapshot
4.7. Market Attractiveness
5. ASIA PACIFIC ANTIBODY-DRUG CONJUGATES MARKET BY TARGET
5.1. CD
5.2. CD
5.3. HER
6. ASIA PACIFIC ANTIBODY-DRUG CONJUGATES MARKET BY INDICATION
5.1. Haematologic Malignancies
5.2. Non-Haematologic Malignancies
7. ASIA PACIFIC ANTIBODY-DRUG CONJUGATES MARKET BY COUNTRY
7.1. China
7.2. India
7.3. Australia
7.4. Others
8. COMPETITIVE INTELLIGENCE
8.1. Market Positioning Matrix and Ranking
8.2. Recent Investments and Deals
8.3. Strategies of Key Players
9. COMPANY PROFILES
9.1. Takeda Pharmaceutical Company Limited
9.2. F. Hoffmann-La Roche Ltd.
9.3. Pfizer Inc.
9.4. Biotest AG
9.5. Astellas Pharma Inc.
9.6. Lonza
